GeNose C-19, a Covid-19 breathalyzer developed by UGM, continues to undergo improvements.
“We will continue GeNose development and research. We are currently completing several publication manuscripts generated from the results of profiling tests and pre-marketing diagnostic tests,” said Dian Kesumapramudya, one of the UGM scientists who developed GeNose, when contacted on Friday (19/2).
Dian added that GeNose is now heading towards the external validation test, one of the processes necessary to complete the post-marketing diagnostic test. It will take place around March-April 2021 conducted by a team of non-UGM researchers.
The team also continues to develop the breathalyzer’s user interface design and artificial intelligence (AI). Dian and his team commit to making the design to be more user-friendly.
“We also develop and evaluate SOPs for screening,” he added.
Currently, GeNose has been operating at three Yogyakarta hospitals, namely Bhayangkara Hospital, dr. Sardjito General Hospital, and UGM Academic Hospital. It has also been a screening alternative for train passengers at eight stations, such as Tugu Station, Senen Station, Gambir Station, Solo Balapan Station, Bandung Station, Cirebon Station, Semarang Tawang Station, and Surabaya Pasar Turi Station. This implementation process is still being monitored, evaluated, and serves as a material for improving GeNose C19.
As is known, GeNose C19 is the first innovation in Indonesia to be used to detect Covid-19 through analyzing breath, whose application is connected to cloud computing and artificial intelligence systems to get real-time diagnosis results. This tool is expected to stop the spread of Covid-19 with the advantages of fast detection, high accuracy, non-invasive, and relatively cheap test costs.
Source: https://ugm.ac.id/id/berita/20782-ugm-terus-kembangkan-genose-alat-skrining-covid-19
